Fundz

Prilenia Closes Oversubscribed $43 Million In Series B Financing Round

PRIVATENov 03, 2021

Amount Raised

$43 Million

Round Type

Series B

BostonBiotechnologyHealth CareTherapeutics

Description

Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announced that it has raised $43M in an oversubscribed Series B financing round. The proceeds will be used to prepare for potential registration and commercialization of its lead drug candidate, pridopidine, for patients with Huntington’s Disease (HD) and Amyotrophic Lateral Sclerosis (ALS), as well as to accelerate timelines and expand the Company’s executive team and operations.

Quick answer

Prilenia raised $43 Million in a Series B round, dated November 3, 2021. Prilenia is based in Boston, Massachusetts, United States.

How much did Prilenia raise?
Prilenia raised $43 Million in a Series B round on November 3, 2021.
What does Prilenia do?
Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders.
Where is Prilenia based and how big is it?
Prilenia is based in Boston, Massachusetts, United States. Fundz records about 60 employees.
Who are the decision-makers at Prilenia?
Fundz holds 1 contact at Prilenia. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at Prilenia, and when

A new round usually means Prilenia is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Prilenia raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Prilenia, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Prilenia. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Prilenia

Location

Boston, Massachusetts, United States

About

Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for the treatment of Huntington’s disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial. The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Prilenia raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Prilenia's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Prilenia raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.